Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01426880 |
Recruitment Status :
Completed
First Posted : September 1, 2011
Last Update Posted : February 15, 2016
|
Sponsor:
German Breast Group
Collaborators:
Teva Pharmaceuticals USA
Roche Pharma AG
GlaxoSmithKline
Information provided by (Responsible Party):
German Breast Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | May 2013 |
Actual Study Completion Date : | August 2013 |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):